Developments in the understanding of the biology and treatment of Hodgkin's disease and non Hodgkin's lymphoma are moving at a rapid pace. New technologies, such as gene expression profiling in malignancy have been implemented using lymphoma to demonstrate their clinical utility. The objective of this volume is to review relevant aspects of the biology, diagnosis, and management with particular emphasis on emerging data available for this disease.

Selected as a Doody’s Core Title for 2023! Comprehensive in scope and thoroughly up to date, Wintrobe’s Clinical Hematology, 15th Edition, combines the biology and pathophysiology of hematology as well as the diagnosis and treatment of commonly encountered hematological disorders. Editor-in-chief Dr. Robert T. Means, Jr., along with a team of expert section editors and contributing authors, provide authoritative, in-depth information on the biology and pathophysiology of lymphomas, leukemias, platelet destruction, and other hematological disorders as well as the procedures for diagnosing and treating them. Packed with more than 1,500 tables and figures throughout, this trusted text is an indispensable reference for hematologists, oncologists, residents, nurse practitioners, and pathologists.  Provides expert coverage of new topics, including COVID-19, palliative care and survivorship, transitioning from pediatric to adult care, and ethical issues in hematology such as management of individuals with religious/cultural objections to transfusion  Integrates WHO classifications of hematologic neoplasms and the latest knowledge in genetics and genomics, and includes focused chapters on hematopoietic cell transplantation, gene therapy, and immunotherapy  Emphasizes four components of diagnosis: the morphology of the peripheral smear, bone marrow, lymph nodes, and other tissues; flow cytometry; cytogenetics; and molecular markers and mutations  Offers fresh perspectives from new section editors Drs. John Leonard (Lymphoma) and Laura Michaelis (Leukemia/MPN), as well as numerous new contributing authors, many of whom provide international viewpoints on hematology    Enrich Your eBook Reading Experience  Read directly on your preferred device(s), such as computer, tablet, or smartphone.  Easily convert to audiobook, powering your content with natural language text-to-speech. 

In recent years a dramatic increase in knowledge of the biology of the lymphomas has been accompanied by the emergence of new treatments offering improvements in efficacy and reduction in toxicity. In this volume an internationally recognized group of experts review relevant aspects of the biology, diagnosis and management, with particular emphasis on the emerging data available for this disease.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.